1,3-Dibromo-5-ethoxy-2-methylbenzene | 1373120-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1,3-Dibromo-5-ethoxy-2-methylbenzene
• 英文别名: 1,3-dibromo-5-ethoxy-2-methylbenzene
• CAS: 1373120-97-8
• 化学式: C₉H₁₀Br₂O
• 分子量: 293.986
• InChiKey: YHUKYNZHQYFZBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-Dibromo-5-ethoxy-2-methylbenzene 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 32.0h， 生成 tert-butyl 4-(5-ethoxy-2-methyl-3-((2-(pyrrolidin-1-yl)ethyl)amino)phenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Pyrazolopyrimidines as dual Akt/p70S6K inhibitors

  摘要：

  Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.011
• 作为产物：
  描述：

  溴乙烷 、 3,5-二溴-4-甲基苯酚 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 1,3-Dibromo-5-ethoxy-2-methylbenzene
  参考文献：
  名称：

  Pyrazolopyrimidines as dual Akt/p70S6K inhibitors

  摘要：

  Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.011

文献信息

• Pyrazolopyrimidines as dual Akt/p70S6K inhibitors
  作者：Kenneth D. Rice、Moon H. Kim、Joerg Bussenius、Neel K. Anand、Charles M. Blazey、Owen J. Bowles、Lynne Canne-Bannen、Diva S.-M. Chan、Baili Chen、Erick W. Co、Simona Costanzo、Steven C. DeFina、Larisa Dubenko、Stefan Engst、Maurizio Franzini、Ping Huang、Vasu Jammalamadaka、Richard G. Khoury、Rhett R. Klein、A.Douglas Laird、Donna T. Le、Morrison B. Mac、David J. Matthews、David Markby、Nicole Miller、John M. Nuss、Jason J. Parks、Tsze H. Tsang、Amy L. Tsuhako、Yong Wang、Wei Xu

  DOI：10.1016/j.bmcl.2012.03.011

  日期：2012.4

  Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development. (C) 2012 Elsevier Ltd. All rights reserved.